McKinsey Opioids Class Action - Sotos Class Actions
OVERVIEW

McKinsey Opioids

Opioid manufacturers created an opioid crisis in Canada and the United States. Some have already pleaded guilty to misrepresenting opioids as a safe and effective treatment for chronic pain. They misrepresented opioids as less addictive than they actually are and failed to react to warning signs that they were being diverted to the black market.

This case alleges that McKinsey counselled the opioid manufacturers on how to do so. As consultants, McKinsey identified doctors susceptible to over-prescribing, crafted messages to misinform doctors, and convinced manufacturers to look the other way when opioids were diverted to the black market.

McKinsey is a leading global consulting firm with annual revenues of more than $10 billion.

The claim seeks to represent all Canadians who were prescribed and became addicted to one of the opioids sold by McKinsey’s clients.

For more information on this and our other class actions, like us on Facebook and follow us on Twitter.

Updates
  • October 15, 2021: Plaintiff issues Statement of Claim in the Ontario Superior Court of Justice
Documents
Contacts

David Sterns

Read more

Louis Sokolov

Read more

Michelle Logasov

Read more

Adil Abdulla

Read more

Karen Whibley

Read more
Signup

Join the class action